Alnylam appealing patent ruling in case against Moderna
oonal


Although Alnylam Pharmaceuticals (NASDAQ:ALNY) agreed with Moderna (NASDAQ:MRNA) on a judgment that the latter's COVID-19 vaccines do not infringe on two for the former's patents, it is filing an appeal of a Delaware federal court's decision.
On Aug. 21, the court issued an order interpreting certain claim terms in two Alnylam (ALNY) patents that the company alleges are used in Moderna's Spikevax vaccines. Although both companies agreed to final judgment of non-infringement in the two patents, Alnylam (ALNY) said it disagrees with the the court's decision and intends to appeal.


Alnylam (ALNY) contends that Moderna has violated five of its patents related to lipid technology used in the latter's mRNA COVID shots.
Separately, Alnylam (ALNY) has also sued Pfizer (PFE) alleging that its COVID vaccines also violate patents.


More on Alnylam Pharmaceuticals

Alnylam: Unlimited Promise Or Unlimited Losses?
Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline
Roche, Alnylam in pact for blood pressure candidate
Alnylam to face FDA AdCom meeting on amyloidosis drug
Alnylam upgraded to outperform at BMO on pipeline opportunities
Seeking Alphaâs Quant Rating on Alnylam Pharmaceuticals
Earnings data for Alnylam Pharmaceuticals